Infect Immun 2000, 68:6321–6328.PubMedCentralPubMedCrossRef 40. Alexander EH, Hudson MC: Factors influencing the internalization of Staphylococcus aureus and impacts on the course of infections in humans. Appl Microbiol Biotechnol 2001, 56:361–366.PubMedCrossRef buy Sotrastaurin 41. Massey RC, Kantzanou MN, Fowler T, Day NP, Schofield K, Wann ER, Berendt AR, Hook M, Peacock SJ: Fibronectin‐binding protein A of Staphylococcus aureus has multiple, substituting, binding regions that mediate

adherence to fibronectin and invasion of endothelial cells. Cell Microbiol 2001, 3:839–851. 42. Lowy FD: Is Staphylococcus aureus an intracellular pathogen? Trends Microbiol 2000, 8:341–343. 43. Sachse F, Becker K, von Eiff C, Metze D, Rudack C: Staphylococcus aureus invades the epithelium in nasal polyposis

and induces IL-6 in nasal epithelial cells in vitro . Allergy 2010, 65(11):1430–1437. 44. Clement S, Vaudaux P, Francois P, Schrenzel J, Huggler E, Kampf S, Chaponnier C, Lew D, Lacroix JS: Evidence of an intracellular reservoir in the nasal mucosa of patients with recurrent Staphylococcus aureus rhinosinositis. J Infect Dis 2005, PF-01367338 in vitro 192:1023–1028. 45. Sinha B, Francois PP, Nusse O, Foti M, Hartford OM, Vaudaux F, Foster TJ, Lew DF, Herrmann M, Krause KH: Fibronectin‐binding protein acts as Staphylococcus aureus invasin via fibronectin bridging to integrin alpha5beta1. Cell Microbiol 1999, 1:101–118. 46. Fowler T, Wann ER, Joh D, Johansson S, Foster TJ, Hook M: Cellular CYTH4 invasion by Staphylococcus aureus involves a fibronectin bridge between the bacterial fibronectin-binding

MSCRAMMs and host cell beta1 integrins. Eur J Cell Biol 2000, 79:672–679.PubMedCrossRef 47. Agerer F, Michel A, Ohlsen K, Hauck CR: Integrin‐mediated invasion of Staphylococcus aureus into human cells requires Src family protein‐tyrosine kinases. J Biol Chem 2003, 278:42524–42531. 48. Fowler T, Johansson S, Wary KK, Hook M: Src kinase has a central role in in vitro cellular internalization of Staphylococcus aureus . Cell Microbiol 2003, 5:417–426. 49. Clem: Bacteriophage for the elimination of methicillin-resistant Staphylococcus aureus (MRSA) colonization and infection. ᅟ: Graduate School Theses and Dissertations; ᅟ. http://​scholarcommons.​usf.​edu/​etd/​2485. 50. Partridge SR: Analysis of antibiotic resistance regions in Gram-negative bacteria. FEMS Microbiol Reviews 2011, 35:820–855.CrossRef 51. Fenton M, Casey PG, Hill C, Gahan CG, Ross RP, McAuliffe O, O’Mahony J, Maher F, Lazertinib manufacturer Coffey A: The truncated phage lysine CHAP k eliminates Staphylococcus aureus in the nares of mice. Bioengineered Bugs 2010, 1:404–407. 52. Paul VD, Rajagopalan SS, Sundarrajan S, George SE, Asrani JY, Pillai R, Chikkamadaiah R, Durgaiah M, Sriram B, Padmanabhan S: A novel bacteriophage Tail-Associated Muralytic Enzyme (TAME) from Phage K and its development into a potent anti-staphylococcal protein. BMC Microbiol 2011, 11:226.PubMedCentralPubMedCrossRef 53. Carlton RM: Phage therapy: past history and future prospects.

PubMedCrossRef 18. Dal Sasso M, Culici M, Bovio C, Braga PC: Gemifloxacin: effects of sub-inhibitory concentrations on various factors affecting bacterial virulence. Int J Selleck AZD9291 Antimicrob Agents 2003, 21:325–333.PubMedCrossRef 19. Dorman CJ, Ni Bhriain N, Higgins CF: DNA supercoiling and environmental regulation of virulence gene expression in Shigella flexneri . Nature 1990, 344:789–792.PubMedCrossRef 20. Mesak LR, Davies J: Phenotypic changes in ciprofloxacin-resistant Staphylococcus aureus . Res Microbiol 2009,

160:785–791.PubMedCrossRef 21. Muto CA, Pokrywka M, Shutt K, Mendelsohn AB, Nouri K, Posey K: A large outbreak of Selleckchem FK866 Clostridium difficile -associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005, 26:273–280.PubMedCrossRef 22. Noren T: Clostridium difficile and the disease it causes. Methods Mol Biol 2010, 646:9–35.PubMedCrossRef 23. Pawlowski SW, Archbald-Pannone L, Carman RJ, Alcantara-Warren C, Lyerly D, Genheimer CW:

Elevated levels of intestinal inflammation in Clostridium difficile infection associated with fluoroquinolone-resistant C. difficile . J Hosp Infect 2009, 73:185–187.PubMedCrossRef 24. Saxton K, Baines SD, Freeman J, O’Connor R, Wilcox MH: Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model. Antimicrob Agents Chemother 2009, 53:412–420.PubMedCrossRef 25. Uchida JPH203 Y, Mochimaru T, Morokuma Y, Kiyosuke M, Fujise M, Eto F: Clonal spread in Eastern Asia of ciprofloxacin-resistant Escherichia coli serogroup O25 strains, and associated virulence factors. Int J Antimicrob Agents 2010, 35:444–450.PubMedCrossRef 26. Drews SJ, Poutanen SM, Mazzulli T, McGeer AJ, Sarabia A, Pong-Porter S: Decreased prevalence of virulence factors among ciprofloxacin-resistant uropathogenic Escherichia coli isolates. J Clin Microbiol 2005, 43:4218–4220.PubMedCrossRef 27. Ferjani S, Saidani M, Ennigrou S, Hsairi M, Ben Redjeb S: Virulence determinants, phylogenetic groups and fluoroquinolone resistance in Escherichia coli isolated from cystitis and pyelonephritis. Pathol

Biol (Paris) 2012, 60:270–274.CrossRef 28. Sun J, Hu J, Peng H, Shi J, Dong Z: Molecular and physiological characterization Obatoclax Mesylate (GX15-070) of fluoroquinolone resistance in relation to uropathogenicity among Escherichia coli isolates isolated from Wenyu River, China. Chemosphere 2012, 87:37–42.PubMedCrossRef 29. Rafii F, Park M, Novak JS: Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones. Antimicrob Agents Chemother 2005, 49:488–492.PubMedCrossRef 30. Rafii F, Park M, Bryant AE, Johnson SJ, Wagner RD: Enhanced production of phospholipase C and perfringolysin O (alpha and theta toxins) in a gatifloxacin-resistant strain of Clostridium perfringens . Antimicrob Agents Chemother 2008, 52:895–900.PubMedCrossRef 31.